A Phase 1 Study of S-3304 in Patients With Solid Tumors

Shionogi32 enrolled

Overview

To determine the maximum tolerated dose and safety profile of S-3304 in patients with biopsy accessible cancer who have failed previous therapy or to whom no standard therapies are available. To determine the pharmacokinetic profile of S-3304 in this patient population

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Solid Tumors

Interventions

S-3304DRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion criteria: * Biopsy proven diagnosis of solid tumor(s) with biopsy accessible lesion(s) * Must be able to tolerate oral medication Exclusion criteria * Patients with other serious illnesses * Patients who are receiving treatments

Locations (4)

University of Colorado Hospital

Denver, Colorado, United States

H. Lee Moffitt Concer Center and Research Institute

Tampa, Florida, United States

Roswell Park Cancer Center

Buffalo, New York, United States

Cleveland Clinic Foundation

Cleveland, Ohio, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.